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Although the treatment of pancreatic ductal adenocarcinoma (PDAC) remains a huge challenge, it is entering a new
era with the development of new strategies and trial designs. Because there is an increasing number of novel
therapeutic agents and potential combinations available to test in patients with PDAC, the identification of robust
prognostic and predictive markers and of new targets and relevant pathways is a top priority as well as the design of
adequate trials incorporating molecular-driven hypothesis. We presently report a consensus strategy for research in
pancreatic cancer that was developed by a multidisciplinary panel of experts from different European institutions and
collaborative groups involved in pancreatic cancer. The expert panel embraces the concept of exploratory early proof
of concept studies, based on the prediction of response to novel agents and combinations, and randomised phase II
studies permitting the selection of the best therapeutic approach to go forward into phase III, where the recommended
primary end point remains overall survival. Trials should contain as many translational components as possible, relying
on standardised tissue and blood processing and robust biobanking, and including dynamic imaging. Attention should
not only be paid to the pancreatic cancer cells but also to microenvironmental factors and stem/stellate cells.
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introduction
Worldwide the incidence of pancreatic ductal adenocarcinoma
(PDAC) continues to increase and ranks as the fourth
commonest cause of cancer death [1]. For all stages, survival at
5 years is <5% [2]. At diagnosis, 50%–60% of patients have
advanced disease with distant metastases and of the 10% or so
of patients who undergo a curative resection, many will relapse
with distant metastases and/or locoregionally [3].
In patients with resectable disease, adjuvant chemotherapy
more than doubles the 5-year survival rate, from 10% with
surgery alone to 25% with postoperative chemotherapy [4–6].
In contrast, level I evidence for adjuvant radiochemotherapy
(RCT) is lacking and its role is still controversial, especially in
Europe [7–10].
In locally advanced PDAC, many studies investigated the role
of chemoradiation. In a qualitative systematic review including
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two systematic reviews, 13 randomised trials and 6
nonrandomised studies, it was shown that RCT is better than
best supportive care, better than radiotherapy alone, but not
better, yet more toxic, than chemotherapy alone [11]. A major
methodological drawback is the fact that the vast majority of
published studies concerns either observational reports or
single-arm prospective studies, with highly selected patient
cohorts. Nevertheless, in a subgroup of patients with
well-controlled localised disease, consolidation RCT may
have a place after several months of upfront chemotherapy
and may offer survival benefit [12]. This strategy is currently
evaluated in an ongoing international phase III trial.
Chemotherapy alone remains the standard of care in this
setting.
In metastatic PDAC, monotherapy with gemcitabine has
remained the main therapeutic option for >10 years [13]. In
phase III studies, many combinations of drugs and new
targeted therapies have been tested with gemcitabine.
Unfortunately, most of these studies are negative and fail to
confer any significant added benefit on overall survival in
comparison with gemcitabine alone. Combinations of
gemcitabine with a fluoropyrimidine or a platinum derivative
have only been associated with a significant improvement in
overall survival in meta-analyses [13–15]. Only one study
evaluating a targeted therapy reports an overall survival
improvement with a combination of erlotinib and gemcitabine,
but this effect is modest with a survival benefit of <2 weeks
[16]. Recently, at 2010 American Society of Clinical
Oncology meeting, the FOLFIRINOX regimen, which
combines the three cytotoxics 5-fluorouracil (5-FU), irinotecan
and oxaliplatin, has shown to confer a significantly longer
progression-free and also overall survival in comparison with
gemcitabine alone [17].
Although the treatment of pancreatic cancer remains a huge
challenge, it is entering a new era with the development of new
strategies and trial designs. Because there is an increasing
number of novel therapeutic agents and potential
combinations available to test in patients with PDAC, the
identification of robust prognostic and predictive markers
and of new targets and relevant pathways is a top priority
[18]. Effective biomarkers will permit stratification of
patients for specific treatments based on molecular-driven
hypotheses. Such strategies should aim to improve overall
survival.
The integration of all these basic, clinical and methodological
issues in the design of new clinical trials is highly desirable if we
want to make substantial progress in pancreatic cancer research
and treatment.
At the initiative of the European Organisation for Research
and Treatment of Cancer Gastrointestinal Group, a consensus
strategy for research in pancreatic cancer was developed by
a multidisciplinary panel of experts from different
European institutions and collaborative groups involved in
pancreatic cancer research and included a 1-day meeting in
Brussels.
The present report summarises the major topics, issues,
challenges and directions addressed by the panel and the
consensus recommendations for guiding research strategies in
pancreatic cancer.
objectives, scope, methods and issues
The main objectives of the meeting were:
 to address critical questions, unmet needs and priorities in
pancreatic cancer treatment and research;
 to discuss and identify consensus areas and collaborations
within the European research network to develop new and
complementary strategies and designs in pancreatic cancer for
the next 3–5 years; and
 to establish and disseminate recommendations from the
European experts panel to the oncology community.
Experts in oncology, surgery, radiotherapy, pathology,
gastroenterology, statistics and basic and translational research
were invited to participate in a 1-day workshop. Before the
meeting, key issues were identified and series of presentations
were prepared summarising the up-to-the-minute status quo of
pancreatic cancer research. The main focus of the meeting was
to integrate current clinical and basic knowledge into the future
investigational strategies.
preclinical models: identification and validation of
new molecular targets/pathways
The search for novel therapeutic approaches to pancreatic cancer
over the past 60 years has been soberly disappointing. Most of
the drugs directed against targets identified in preclinical studies
have not been able to demonstrate a clinically relevant benefit for
patients with pancreatic cancer. In contrast, many potential
targets have yet to be evaluated in part due to the lack of
appropriate in vivo models. Therefore, there is an urgent need to
(i) develop and apply suitable high-throughput screening
strategies to identify novel functionally relevant targets and (ii)
use appropriate preclinical in vivo models recapitulating the
human situation to validate putative drug targets in vivo.
For screening strategies aiming at identifying novel
therapeutic targets, cancer cell lines and tissues traditionally
represent the input material for DNA genomic studies (array
comparative genomic hybridisation, single-nucleotide
polymorphism, copy number variation, deep sequencing), RNA
expression (complementary DNA microarray, microRNA
arrays, alternative splicing) and epigenetic studies
(decodification of the histone code, including acetylation,
phosphorylation and methylation in PDAC) [19, 20]. More
recently, both cancer tissues and serum samples have been
exploited as a resource for proteomics (two-dimensional
polyacrylamide gel electrophoresis, matrix-assisted laser
desorption/ionisation-time-of-flight, surface-enhanced laser
desorption/ionisation-time-of-flight). Identification of
circulating predictive or prognostic markers in serum rather
than tumour tissue may be very rewarding in a disease where
obtaining tissue remains a challenge. The advent of several new
technologies has opened up the possibility to functionally
screen distinct groups of genes ranging from promising drug
targets up to the whole genome. These loss-of-function screens
use RNA interference libraries that are able to knock down the
expression of multiple genes, the impact of which on cell
viability, migration or drug resistance can be measured
simultaneously in a high-throughput manner.
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The therapeutic yield of the in vitro screening approaches for
target identification has been limited by the fact that pancreatic
cancer is characterised by an extremely high proportion of
stromal cells surrounding the cancer cells. This might be one
important explanation, why novel drugs, although effective in
vitro, frequently fail to show a clinical benefit in vivo in
subsequent trials. Therefore, preclinical in vivo models are
essential that may recapitulate the cross talk between different
tumour and stromal components that is able to enhance
tumour cell survival, cancer progression and the resistance to
most therapeutic strategies well known to the clinician [21, 22].
The close interaction between tumour cells and
inflammatory and mesenchymal microenvironment is able to
modulate the growth characteristics of the tumour leading to
phenomena such as epithelial to mesenchymal transition of the
tumour cells with increased invasiveness and resistance to
apoptosis. Moreover, the cross talk between tumour and
stromal cells also affects the vascularity of the stroma,
frequently resulting in a hypovascular stroma that impairs the
accessibility of the tumour cells by anticancer drugs [23].
Recent data also suggest that tumour–stroma interactions also
affect the niche of multidrug-resistant cells, including cancer
stem cells. An earlier attempt to overcome the limitations of in
vitro assays was to use xenograft models with subcutaneous or
orthotopic implantation of (human) tumour cells in
immunocompromised mice [23, 24]. Although therapeutic
approaches may work well in mouse xenografts, these
frequently fail in patients, limiting the interpretation and
transferability of xenograft data to human PDAC.
In recent years, genetically engineered mouse models have
been developed that have been based on the predominant
molecular alterations seen in the human disease and better
recapitulate the morphological features of human pancreatic
cancer [25–27]. Their marked stromal reaction resembles
human disease quite strikingly. Hence, these genetic mouse
models are more promising for the identification of new targets
and validation of novel drugs. However, genetically engineered
models also have limitations. Mouse tumours exhibit
a different tumour biology and do not reflect the genetic
heterogeneity of human tumours. Furthermore, correlative
studies between human and murine tissues are often hampered
by different antibody affinities.
Beyond the use of mouse models, preclinical validation must
also focus on human pancreatic cancer tissues. Expression levels
of potential drug targets have to be assessed and correlated to
clinical parameters such as survival and response to different
drugs. Validation with prospective and standardised human
tissue sampling is therefore essential to improve the transfer of
potential drug targets into the clinic. Ideally, tissue sampling
should be carried out in the context of prospective studies
accompanied by a translational programme that allows
identification of predictive and prognostic markers as well as
validation of potential drug targets in a standardised manner.
Evaluation of target expression levels in human tissues does
not usually predict response to a given drug in vivo. To
overcome this obstacle, ex vivo chemosensitivity testing has
been developed to assess the efficacy of novel drugs with human
material prospectively. Chemosensitivity assays are intended to
predict the sensitivity of cells derived from pancreatic tumours
at the time of surgery or biopsy to chemotherapeutic drugs or
novel agents, with the intent of identifying more effective
treatment protocols that would translate into improved clinical
survival. A variety of sensitivity assays have been developed in
other cancers and various attempts are ongoing to establish and
prospectively validate these chemosensitivity assays in
pancreatic cancer. The ultimate goal of these assays is to
develop a chimiogram, similar to the concept of an
antibiogram, using single or combined anticancer drugs to
establish a profile of sensitivity or resistance for a particular
patient. It needs to be determined whether the promising
results obtained in other cancer entities can be translated to
pancreatic cancer [28].
In parallel with the research on pancreatic cancer per se,
attention should also be paid to the exploration of susceptibility
genes for pancreatic cancer [29], which may enable the
identification of more groups of individuals at increased risk of
developing pancreatic cancer than are currently known. This
may guide the development of preventive strategies as well as
novel targets for drug development.
collection of biospecimens, biobanking
Emphasis should be made on the prospective collection of well-
annotated tumour material and blood from patients, preferably
within the context of clinical trials. To avoid variability in
biospecimen collection, processing and storage, pathologists
and basic researchers should harmonise these processes within
the framework of internationally agreed guidelines and
standard operating procedures [30].
functional imaging
Functional imaging by diffusion-weighted magnetic resonance
imaging (MRI), perfusion MRI/computed tomography (CT) or
positron emission tomography (PET) protocols represents an
interesting tool avenue to elucidate the mechanism of action of
drugs (cytotoxic, antiangiogenic and antistromal), to assess
efficacy of drugs and to identify (non)-responders early on in
the treatment process.
Dynamic contrast-enhanced MRI is a noninvasive imaging
technique already used in the staging of pancreatic cancer. The
intravenous administration of a gadolinium-based contrast
agent is needed to carry out the study. The acquired data can be
analysed using a pharmacokinetic model to obtain quantitative
parameters: these are blood flow and contrast transfer
coefficient (Ktrans) related to tissue perfusion/permeability, vi
representing the tissue volume fraction occupied by the
extravascular extracellular space and vp representing the tissue
volume fraction occupied by the intravascular space [31].
Previous publications have reported the technical feasibility and
reproducibility of the technique and its utility in monitoring
treatment response in nonresectable pancreatic ductal
adenocarcinoma ([32, 33] and M. A. Bali, unpublished data).
So far, functional imaging is restricted to academic centres
and is being increasingly adopted in early phase I/II clinical
trials for correlative studies. Efforts should be made to
standardise image acquisition, definition of target lesions and
well-defined assessment of response. Validation (e.g. by
pathological correlation) of functional imaging is considered
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equally important. Offering technical and logistical platforms
for central reviewing is a priority.
integrating surgery in multimodal therapy and
research
There is still room for improving the outcome of patients with
pancreatic cancer following R0 or R1 resection, in the era of
adjuvant gemcitabine. Results may be improved by selecting the
patients who are more likely to benefit from a particular drug
regimen. Results are still awaited concerning the human
equilibrative nucleoside transporter 1 (hENT1) testing to
identify gemcitabine sensitivity in the context of the completed
ESPAC-3 trial. Patients who are less likely to benefit from
gemcitabine may be candidates for another drug regimen (5-FU
based) [34]. The recent results of the (modified) FOLFIRINOX
combination in the advanced setting asks questions about the
potential advantages for using this regimen in the
(neo)adjuvant setting but careful consideration is needed in the
trial design to take this forward given the significantly increased
toxicity [17, 35].
Level I evidence for the use of neoadjuvant
chemo(radio)therapy in patients with resectable pancreatic
cancer is lacking, as all of the attempted clinical trials in the past
have failed to complete target recruitment. Continuing
challenges in any trial design include biliary obstruction, the
need for histological proof and psychological factors related to
postponing surgery and the fear of progression. There are less
problems for the conduct of neoadjuvant strategies in
borderline resectable tumours, provided that consensus is
reached upon definition of resectability on imaging and margin
positivity by expert radiologists and surgeons. The planned
ESPAC-5 study is a randomised phase II study that will explore
three different strategies: upfront surgery, chemotherapy
followed by surgery and chemoradiotherapy before resection.
All patients will be offered postoperative chemotherapy. The
primary end point of this trial will be resectability. In this trial,
there are explicit criteria to judge resectability and central
imaging review before randomisation.
In this setting, all experts agreed on the value of randomised
phase II studies before embarking on large phase III trials with
survival as primary end point. No consensus was reached on
the most appropriate end point of neoadjuvant protocols for
borderline resectable tumours, but the percentage of R0
resections or the pathologically documented response rate in
case of preoperative therapy may be less subjective than
resectability per se.
remaining challenges with radiation therapy
RCT has shown disappointing results in locally advanced
pancreatic cancer (LAPC). Apart from pain palliation and
a modest survival gain over best supportive care or radiation
alone, response rates are low [11, 36, 37]. This may be partly
due to an underestimation by radiological measurement. PDAC
is in general a tumour with a large stromal component and
therefore less likely to shrink radiologically, despite a possible
response from cancer cells. Functional imaging may be more
appropriate to measure response for LAPC. Response rates to
RCT are best measured in studies carried out in the
neoadjuvant setting; 53 of these studies were carried out in
patients with borderline resectable PDAC and the mean
response rate of RCT was 29%, with a great variation between
individual studies [38]. In these preoperative RCT studies, an
invariably high R0 resection rate is reported, as well as
a variable but high resection rate. Some of these studies report
a high survival rate compared with historical control groups of
patients with primarily resectable tumours [39]. A major
methodological flaw of these preoperative RCT studies is
that none of them is randomised and they all report the
results of the subset of patients who actually underwent
a resection, rather then reporting by intention to treat [38, 39].
Hence, the potential benefit of increasing the resection rate is
not taken into account. This also applies to the aforementioned
systematic review [38]. Another methodological disadvantage
of single-arm phase II studies in PDAC is that a small
difference in selection of patients may have a relatively great
impact on outcome, making comparison between studies
hazardous. Future phase II or III clinical studies of
preoperative RCT should at least report by intention to treat
and preferably be randomised comparisons in well-defined
patient cohorts.
Despite the aforementioned methodological shortcomings,
literature appears to indicate that preoperative RCT in
borderline resectable and presumably also primarily resectable
PDAC may improve resection rate, R0 resection rate and
possibly overall survival [38, 39]. This hypothesis is valid and
should be tested in randomised prospective studies.
issues and future of systemic therapy
The FOLFIRINOX regimen is the first gemcitabine-free
regimen that has shown to be more efficient than gemcitabine
in patients with good performance status (PS = 0–1), metastatic
pancreatic cancer mainly of the body of the pancreas and
younger than 76 years. The FOLFIRINOX regimen significantly
improved overall survival and progression-free survival in all
prognostic subgroups. The combination delayed definitive
degradation of quality of life for all dimensions (except
diarrhoea). However, the regimen was associated with more
grade 3/4 toxic effects than gemcitabine including diarrhoea
(12.3; 1.6%), nausea (15.6; 6.3%), vomiting (17.2; 6.3%),
fatigue (24; 14.3%), neutropenia (47.9; 19.2%) and febrile
neutropenia (5.7; 0%) [17, 35].
More information is needed on the usefulness of
granulocyte–macrophage colony-stimulating factor, the safety
beyond 70 years and in patients with jaundice. Despite some
uncertainties and data from a routine use, FOLFIRINOX may
be considered a standard of care in patients with metastatic
pancreatic cancer who fulfil the following selection criteria:
normal bilirubin, good performance status (Eastern
Cooperative Oncology Group 0 or 1) and no cardiac ischaemia.
FOLFIRINOX is not yet easily available in many European
countries, where gemcitabine remains the only standard of care.
In the near future, the schedule of FOLFIRINOX may likely be
optimised and simplified, with the role of 5-FU bolus being
questioned. More information and data on its use in routine
practice are also needed, as well as the relative contribution of
each of its component. The oxaliplatin–5-FU-based
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combination also appears to be a valuable alternative, as shown
in the second-line setting [40].
Targeted therapy remains experimental in PDAC and there is
no clearly relevant predictive marker to use erlotinib more
selectively [41].
The future use of predictive biomarkers will likely help us to
determine how and when such drugs have to be given in daily
clinical practice and research settings [42].
specific considerations for trial designs in
advanced pancreatic cancer
Randomised phase II studies are the best way to explore activity
of drugs and/or strategies, before embarking on phase III
studies. Single-arm phase II studies have many intrinsic flaws.
The main disadvantage of single-arm studies is the fact that the
results are very dependent upon patient selection, making it
practically impossible to compare results with those of other
single-arm studies.
Attention should also be paid to a proper selection of
patients, based upon well-defined and uniform protocols of
defining disease stage (metastatic versus locally advanced versus
borderline resectable versus primarily resectable disease),
performance status and predictive markers, if available. Study
results should be reported by intention to treat. Moreover,
international consensus should be sought on how to define and
report pathological issues such as accurate distance to the
retroperitoneal margin. Also, the reporting of end points
should become more uniform than it is to date. Translational
research should be added to as many prospective studies as
possible, with the intention of identifying predictive markers
for new therapies and acquiring a better understanding of the
disease as such. In this respect, gemcitabine nucleoside
transporters (hENT1, possibly hCNT3) and deoxycytidine
kinase (dCK) involved in the metabolism of gemcitabine
should be incorporated in all future trials, aiming to stratify
patients for gemcitabine benefit once the assays have been
formally validated [43–45].
Preferentially driven by predictive biomarkers, new
targeted agents and perhaps combinations of targeted
agents should be evaluated in combination with either
gemcitabine or FOLFIRINOX, preferentially in phases II
randomised studies.
executive summary
 Use preclinical genetically engineered mouse or xenograft
models, and then human tumour tissue to support
exploration and assessment of new drugs and targets.
 Collect tumour tissue and blood specimens in the setting of
future research and trials; define standard operating procedures
for the collection of these specimens, the extraction and
preparation of DNA, RNA and proteins, and the storage.
Tumour tissue should be obtained by needle puncture, either
preoperatively or in locally advanced or metastatic settings in
the primary tumour or accessible metastases, preferably by
sampling core-biopsies; all resected specimens should also be
stored within a standardised biobanking process; and facilities
for the assessment of prognostic and predictive markers.
Specific attention should be paid to standardised processing
(inking) and pathological evaluation of the resected specimen
in order to adequately determine R0 versus R1 resection,
focusing on the accurate distance to the retroperitoneal margin.
 Develop and standardise a dynamic imaging platform (PET–
CT, diffusion and perfusion MRI) to be incorporated in the
early evaluation of new drugs and regimens according to the
specific therapeutic intervention type, such as
antiproliferative, antistromal and antiangiogenic. All the
dynamic imaging parameters should be evaluated,
standardised and validated to be used within a specific time
schedule, a specific tumour setting and in a multicentre and
reproducible way.
 Integrate optimal surgery (aiming at a true R0 resection) in
a multimodal management and research setting by
developing specific trials according to the resectability status
of the tumour as assessed by a board of expert pancreatic
surgeons, radiologists and pathologists; the best treatment of
resectable tumours should be explored in both the adjuvant
and the neoadjuvant settings; newer active regimens in
advanced disease such as FOLFIRINOX should be tested after
resection; neoadjuvant short-window pilot protocols
incorporating new drugs or new regimens are encouraged in
the setting of proof-of-concept studies in highly selected
centres that can support the complex protocols (preoperative
tissue sampling, biliary drainage, repeated functional
imaging, delivery of new drugs, etc.).
Borderline resectable tumours should be accurately defined by
the degree of vascular encasement and offered to downstaging
therapeutic protocols combining either active multidrug
regimens or RCT; R0 resectability rate, as a surrogate of
disease-free survival or overall survival, is supported as the
primary end point in randomised phase II trials.
 Consider the FOLFIRINOX regimen as a new standard
option in selected patients; additional data from routine
clinical practice and possible simplification of the regimen are
both desirable; FOLFIRINOX may be evaluated in phase I/II
studies with new partners in advanced disease; however,
gemcitabine remains the gold standard and the backbone for
new combinations in the general population of PDAC
patients.
 Aim to identify patients who will derive particular benefit
from gemcitabine exposure and those who should be treated
with non-gemcitabine-based combinations; hENT1, dCK or
ribonucleotide reductase M1/2 are credible candidates to be
explored and then validated in clinical trials.
 Separate tumour settings for appropriate trials and end
points, including metastatic, locally advanced, borderline
resectable and resectable disease.
 Design randomised phase II proof-of-concept studies to
explore new agents aiming to obtain positive signals of
antitumour activity, supported by biomarker and functional
imaging responses. Develop phase III designs that will enable
more than one new agent and pathway to be assessed.
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major conclusions, expectations and
recommendations
The prognosis of patients with pancreatic cancer remains very
poor. Surgery can yield long-term disease-free survival and further
improvement is seen with adjuvant chemotherapy. Preclinical and
early clinical research should focus on the mechanisms and
prediction of response/nonresponse to therapeutic strategies.
Attention should not only be paid to the pancreatic cancer cells
but also to the microenvironmental factors and stem/stellate cells.
To move the field of clinical pancreatic cancer research
forward, the expert panel recommends that the following steps
should be taken:
 Define uniform classifications for disease stage and
radiological resectability. The pathology of resection
specimens and biopsies from unresectable local disease as well
as metastases should be handled and reported uniformly.
Define in a uniform manner specific groups of patients for
various areas of clinical research, namely resectable, borderline
resectable, locally advanced and metastatic. Define uniform
criteria to report treatment results and end points in clinical
studies. It is essential to analyse results by intention to treat.
 Treat as many patients as possible in the framework of
prospective clinical studies. Studies should contain as many
translational components as possible, including dynamic
imaging. The expert panel embraces the concept of
exploratory early proof of concept studies and randomised
phase II studies. The choice of end points in phase II studies
should be objective permitting the selection of the best
therapeutic approach to go forward into phase III, where the
recommended primary end point remains overall survival.
 Collection of tumour material and blood for translational
research is warranted for all studied patients; preferably, core
needle biopsies should be taken before treatment, also in
patients with locally advanced disease and/or distant
metastases participating in studies. Depending upon the study,
tumour material should also be obtained after treatment.
Biobanks should be set up using standardised operating
procedures. Fundamental translational research with these
tissues should be directed towards prognostic and predictive
factors, response assessment and so on, specific for the study at
stake. Not only the cancer cells but also the microenvironment
should be taken into account. In addition, the biobanks
should be used to find new pathways and eventually new
targeted drugs. High-throughput in vitro systems and clever in
vivo models should be used to increase the efficacy of bringing
eventual new targeted therapies into clinical research.
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